Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
There is increasing recognition that pathogenic germ line variants drive the development of hematopoietic cancers in many individuals. Currently, patients with hereditary hematologic malignancies (HHMs) receive similar standard therapies and hematopoietic stem cell transplant (HSCT) approaches as those with sporadic disease. We hypothesize that patients with myeloid malignancies and deleterious germ line predisposition variants have different posttransplant outcomes than those without such alleles. We studied 472 patients with myeloid neoplasms, of whom 26% had deleterious germ line variants and 34% underwent HSCT. Deleterious germ line variants in CHEK2 and DDX41 were most commonly seen in American and Australian cohorts, respectively. Patients with deleterious germ line DDX41 variants had a higher incidence of severe (stage 3-4) acute graft-versus-host disease (GVHD) (38%) than recipients with deleterious CHEK2 variants (0%), other HHM variants (12%), or patients without such germ line variants (9%) (P = .002). Importantly, the use of posttransplant cyclophosphamide reduced the risk of severe acute GVHD in patients receiving HSCT for deleterious germ line DDX41-associated myeloid neoplasms (0% vs 53%, P = .03). Based on these results, we advocate the use of posttransplant cyclophosphamide when individuals with deleterious germ line DDX41 variants undergo allogeneic HSCT for myeloid malignancies, even when transplantation has been performed using wild-type donors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 4 vom: 28. Feb., Seite 549-554 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saygin, Caner [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8N3DW7272P |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 23.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2022008172 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345199138 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345199138 | ||
| 003 | DE-627 | ||
| 005 | 20231226024524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2022008172 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345199138 | ||
| 035 | |a (NLM)36001442 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saygin, Caner |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a There is increasing recognition that pathogenic germ line variants drive the development of hematopoietic cancers in many individuals. Currently, patients with hereditary hematologic malignancies (HHMs) receive similar standard therapies and hematopoietic stem cell transplant (HSCT) approaches as those with sporadic disease. We hypothesize that patients with myeloid malignancies and deleterious germ line predisposition variants have different posttransplant outcomes than those without such alleles. We studied 472 patients with myeloid neoplasms, of whom 26% had deleterious germ line variants and 34% underwent HSCT. Deleterious germ line variants in CHEK2 and DDX41 were most commonly seen in American and Australian cohorts, respectively. Patients with deleterious germ line DDX41 variants had a higher incidence of severe (stage 3-4) acute graft-versus-host disease (GVHD) (38%) than recipients with deleterious CHEK2 variants (0%), other HHM variants (12%), or patients without such germ line variants (9%) (P = .002). Importantly, the use of posttransplant cyclophosphamide reduced the risk of severe acute GVHD in patients receiving HSCT for deleterious germ line DDX41-associated myeloid neoplasms (0% vs 53%, P = .03). Based on these results, we advocate the use of posttransplant cyclophosphamide when individuals with deleterious germ line DDX41 variants undergo allogeneic HSCT for myeloid malignancies, even when transplantation has been performed using wild-type donors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Roloff, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Hahn, Christopher N |e verfasserin |4 aut | |
| 700 | 1 | |a Chhetri, Rakchha |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Saar |e verfasserin |4 aut | |
| 700 | 1 | |a Elmariah, Hany |e verfasserin |4 aut | |
| 700 | 1 | |a Talati, Chetasi |e verfasserin |4 aut | |
| 700 | 1 | |a Nunley, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Guimin |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Aelin |e verfasserin |4 aut | |
| 700 | 1 | |a Bishop, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kosuri, Satyajit |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Soma |e verfasserin |4 aut | |
| 700 | 1 | |a Singhal, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Venugopal, Parvathy |e verfasserin |4 aut | |
| 700 | 1 | |a Homan, Claire C |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Hamish S |e verfasserin |4 aut | |
| 700 | 1 | |a Hiwase, Devendra |e verfasserin |4 aut | |
| 700 | 1 | |a Godley, Lucy A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 4 vom: 28. Feb., Seite 549-554 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:4 |g day:28 |g month:02 |g pages:549-554 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2022008172 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 4 |b 28 |c 02 |h 549-554 | ||